NCT04833504 is a clinical trial recently completed in which CD19+ CAR T-cells expressing IL-7 and CCL19 were tested in patients with relapsed or refractory B-cell lymphoma, however the results have not yet been reported. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.